Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Myriad Genetics (MYGN) Deferred Taxes (2016 - 2025)

Myriad Genetics has reported Deferred Taxes over the past 16 years, most recently at $100000.0 for Q4 2025.

Quarterly Deferred Taxes fell 50.0% to $100000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, up 60.71% year-over-year, with the annual reading at $100000.0 for FY2025, 103.57% up from the prior year.
Deferred Taxes was $100000.0 for Q4 2025 at Myriad Genetics, down from $200000.0 in the prior quarter.
Over five years, Deferred Taxes peaked at $600000.0 in Q1 2024 and troughed at -$16.3 million in Q3 2021.
The 5-year median for Deferred Taxes is -$2.2 million (2024), against an average of -$4.1 million.
Year-over-year, Deferred Taxes plummeted 1666.67% in 2022 and then surged 500.0% in 2024.
A 5-year view of Deferred Taxes shows it stood at -$4.3 million in 2021, then plummeted by 104.65% to -$8.8 million in 2022, then surged by 73.86% to -$2.3 million in 2023, then surged by 108.7% to $200000.0 in 2024, then crashed by 50.0% to $100000.0 in 2025.
Per Business Quant, the three most recent readings for MYGN's Deferred Taxes are $100000.0 (Q4 2025), $200000.0 (Q4 2024), and -$1.4 million (Q3 2024).